Identification of GPR52 antagonists as potential treatments for Huntington Disease

鉴定 GPR52 拮抗剂作为亨廷顿病的潜在治疗方法

• 批准号: 9205646
• 负责人: Marc Ferrer
• 金额: $ 1.9万
• 依托单位: NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9205646
• 关键词: Identification; GPR52; antagonists; potential; treatments

During this period, the NCGC has fostered and maintained over 180 active collaborations with both NIH and extramural investigators, facilitating drug discovery efforts across the entire spectrum of human disease. These efforts have led to over 100 high-throughput screens and nearly 60 medicinal chemistry campaigns, providing our collaborators and the general research community a wealth of publications and promising small molecule leads. In addition, the NCGC has undertaken a number of informatic challenges to make better use of existing drug and disease target information and provide the general public with easily accessible resources, further catalyzing the development of new therapies for human disease.

在此期间，NCGC与NIH和壁外研究人员培养并维持了180多次主动合作，从而促进了整个人类疾病范围内的药物发现工作。 这些努力导致了100多个高通量屏幕和近60种药物化学运动，为我们的合作者和一般研究社区提供了丰富的出版物和有望的小分子铅。 此外，NCGC提出了许多信息挑战，以更好地利用现有的药物和疾病目标信息，并为公众提供易于获得的资源，从而进一步促进了针对人类疾病的新疗法的发展。